Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Rudusky B. M.
Northeastern Cardiovascular Clinic Research Institute, Wilkes-Barre, PA, USA
Atrial fibrillation is the most frequent cardiac arrhythmia associated with morbid consequences, comorbid disease states and problematic management. All therapeutic measures presently available are lacking in terms of safety, efficacy or both, to a greater or lesser degree. Past and recent interests in intermittent pharmacologic treatment of paroxysmal atrial fibrillation has received minimal attention. A 70-year-old white male presented to his cardiologist for a sudden bout of new onset atrial fibrillation. Over a period of 6 ½ years he sustained 8 bouts of atrial fibrillation all successfully treated with intermittent pharmacotherapy by one or two doses of a selected therapeutic program based on the combination of old and more recent pharmacologic strategies. Intermittent pharmacotherapy of paroxysmal atrial fibrillation in properly selected patients merits continued observation and consideration. Avoidance of side-effects of continuous drug therapy and decrease in economic costs, especially in view of the expanding number of older patients subjected to polypharmacy are positive benefits.